Nemvaleukin alfa

Nemvaleukin alfa (ALKS 4230) is a IL-2 fusion protein that selectively binds to intermediate-affinity IL-2R. Nemvaleukin alfa is an activator of NK and effector T cells. Nemvaleukin alfa can be used for research of cancer[1][2][3].

Product Specifications

CAS Number

[2315268-27-8]

Product Name Alternative

ALKS 4230; RDB-1450

UNSPSC

12352203

Target

Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/nemvaleukin-alfa.html

Purity

99.50

Solubility

10 mM in DMSO

Smiles

[Nemvaleukinalfa]

Molecular Weight

(34.41 kDa)

References & Citations

[1]Pan Y, et al, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer. J Immunother Cancer. 2022 Sep;10 (9) :e004913. |[2]Lopes JE, et al. Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus Monkeys. J Pharmacol Exp Ther. 2021 Nov;379 (2) :203-210. |[3]Lopes JE, et al. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J Immunother Cancer. 2020 Apr;8 (1) :e000673.